ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 309, Issue 8, 2015, Pages H1271-H1280

  Belmonte, Frances ^a   Das, Samarjit ^b   Sysa Shah, Polina ^c   Sivakumaran, Vidhya ^c   Stanley, Brian ^c   Guo, Xin ^c   Paolocci, Nazareno ^c   Aon, Miguel A ^c   Nagane, Masaki ^d   Kuppusamy, Periannan ^d   Steenbergen, Charles ^b   Gabrielson, Kathleen ^a,b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

ErbB2; Glutathione peroxidase; Mitochondria; NRTK; Reactive oxygen species

Indexed keywords

ABELSON KINASE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 1; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); THIOREDOXIN; THIOREDOXIN REDUCTASE 2; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ARG TYROSINE KINASE; ERBB2 PROTEIN, MOUSE; ERBB2 PROTEIN, RAT; GLUTATHIONE REDUCTASE; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CELL DEATH; CELL ISOLATION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART FUNCTION; HEART MITOCHONDRION; HEART MUSCLE CELL; MITOCHONDRIAL RESPIRATION; MOUSE; MTT ASSAY; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CELL LINE; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEART DISEASES; METABOLISM; NEWBORN; PATHOLOGY; RAT; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, NEWBORN; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL DEATH; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HEART DISEASES; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA, HEART; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; RATS; REACTIVE OXYGEN SPECIES; RECEPTOR, ERBB-2;

EID: 84944381935     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00517.2014     Document Type: Article

References (72)

1. Aon MA, Cortassa S, O’Rourke B. Redox-optimized ROS balance: a unifying hypothesis. Biochim Biophys Acta 1797: 865–877, 2010.
2. Aon MA, Stanley BA, Sivakumaran V, Kembro JM, O’Rourke B, Paolocci N, Cortassa S. Glutathione/thioredoxin systems modulate mitochondrial H2O2 emission: an experimental-computational study. J Gen Physiol 139: 479–491, 2012.
3. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med 345: 995–996, 2001.
4. Burden S, Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 18: 847–855, 1997.
5. Cao C, Leng Y, Huang W, Liu X, Kufe D. Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases. J Biol Chem 278: 39609–39614, 2003.
6. Cao C, Leng Y, Kufe D. Catalase activity is regulated by c-Abl and Arg in the oxidative stress response. J Biol Chem 278: 29667–29675, 2003.
7. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34: 106–135, 2014.
8. Chislock EM, Ring C, Pendergast AM. Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci USA 110: 12432–7, 2013.
9. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J, Chien KR, Lee KF. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459–465, 2002.
10. Das S, Wong R, Rajapakse N, Murphy E, Steenbergen C. Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ Res 103: 983–991, 2008.
11. Davies a KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 261: 3060–3067, 1986.
12. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 28: 506–514, 1996.
13. Dhalla AK, Singal PK. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am J Physiol Heart Circ Physiol 266: H1280–H1285, 1994.
14. Dikalov S, Skatchkov M, Fink B, Bassenge E. Quantification of superoxide radicals and peroxynitrite in vascular cells using oxidation of sterically hindered hydroxylamines and electron spin resonance. Nitric Oxide 1: 423–431, 1997.
15. Dikalov SI, Kirilyuk IA, Voinov M, Grigorév IA. EPR detection of cellular and mitochondrial superoxide using cyclic hydroxylamines. Free Radic Res 45: 417–430, 2011.
16. Doroshow JH, Daviesa KJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem 261: 3068–3074, 1986.
17. Flohé L, Otting F. Superoxide dismutase assays. Methods Enzymol 105: 93–104, 1984.
18. Frijhoff J, Dagnell M, Godfrey R, Ostman A. Regulation of protein tyrosine phosphatase oxidation in cell adhesion and migration. Antioxid Redox Signal 20: 1994–2010, 2014.
19. Gabrielson K, Bedja D, Pin S, Tsao A, Gama L, Yuan B, Muratore N. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res 67: 1436–1441, 2007.
20. Gabrielson KL, Hogue BA, Bohr VA, Cardounel AJ, Nakajima W, Kofler J, Zweier JL, Rodriguez ER, Martin LJ, de Souza-Pinto NC, Bressler J. Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in mice. Am J Pathol 159: 1507–1520, 2001.
21. Giraud MN, Fluck M, Zuppinger C, Suter TM. Expressional reprogramming of survival pathways in rat cardiocytes by neuregulin-1beta. J Appl Physiol 99: 313–322, 2005.
22. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8: 11, 2011.
23. Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, Naik TJ, Prasad SV, Ardehali H. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 284: 2080–2087, 2009.
24. Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ, Rosenzweig A. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 44: 2231–2238, 2004.
25. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 13: 559–571, 2013.
26. Gupta M, Singal PK. Higher antioxidative capacity during a chronic stable heart hypertrophy. Circ Res 64: 398–406, 1989.
27. Hasinoff BB, Patel D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol Appl Pharmacol 249: 132–139, 2010.
28. Henjes F, Bender C, von der Heyde S, Braun L, Mannsperger HA, Schmidt C, Wiemann S, Hasmann M, Aulmann S, Beissbarth T, Korf U. Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis 1: e16, 2012.
29. Hu W, Lu S, McAlpine I, Jamieson JD, Lee DU, Marroquin LD, Heyen JR, Jessen BA. Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase. Toxicol Sci 129: 188–199, 2012.
30. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341–354, 2005.
31. Imahashi K, Schneider MD, Steenbergen C, Murphy E. Transgenic expression of Bcl-2 modulates energy metabolism, prevents cytosolic acidification during ischemia, and reduces ischemia/reperfusion injury. Circ Res 95: 734–741, 2004.
32. Janssen AJ, Trijbels FJ, Sengers RC, Smeitink JA, van den Heuvel LP, Wintjes LT, Stoltenborg-Hogenkamp BJ, Rodenburg RJ. Spectrophotometric assay for complex I of the respiratory chain in tissue samples and cultured fibroblasts. Clin Chem 53: 729–734, 2007.
33. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908–916, 2006.
34. Kirshenbaum LA, Hill M, Singal PK. Endogenous antioxidants in isolated hypertrophied cardiac myocytes and hypoxia-reoxygenation injury. J Mol Cell Cardiol 27: 263–272, 1995.
35. Kowaltowski AJ, de Souza-Pinto NC, Castilho RF, Vercesi AE. Mitochondria and reactive oxygen species. Free Radic Biol Med 47: 333–343, 2009.
36. Kuramochi Y, Cote GM, Guo X, Lebrasseur NK, Cui L, Liao R, Sawyer DB. Cardiac endothelial cells regulate reactive oxygen speciesinduced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem 279: 51141–7, 2004.
37. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 70: 343–354, 2005.
38. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, Rhee SG. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci USA 101: 16419–16424, 2004.
39. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378: 394–398, 1995.
40. Leitch JM, Jensen LT, Bouldin SD, Outten CE, Hart PJ, Culotta VC. Activation of Cu,Zn-superoxide dismutase in the absence of oxygen and the copper chaperone CCS. J Biol Chem 284: 21863–21871, 2009.
41. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 51: 174–181, 2002.
42. Long J, Ma J, Luo C, Mo X, Sun L, Zang W, Liu J. Comparison of two methods for assaying complex I activity in mitochondria isolated from rat liver, brain and heart. Life Sci 85: 276–280, 2009.
43. Ma J, Wang Y, Zheng D, Wei M, Xu H, Peng T. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways. Cardiovasc Res 97: 77–87, 2013.
44. May JM, de Haën C. Insulin-stimulated intracellular hydrogen peroxide production in rat epididymal fat cells. J Biol Chem 254: 2214–2220, 1979.
45. Merten KE, Jiang Y, Feng W, Kang YJ. Calcineurin activation is not necessary for doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway. J Pharmacol Exp Ther 319: 934–940, 2006.
46. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 417: 1–13, 2009.
47. Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59: 1–12, 2004.
48. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52: 1213–1225, 2012.
49. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159–3167, 2000.
50. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hübner N, Chien KR, Birchmeier C, Garratt AN. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 99: 8880–8885, 2002.
51. Pugatsch T, Abedat S, Lotan C, Beeri R. Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. Breast Cancer Res 8: R35, 2006.
52. Qiu Z, Cang Y, Goff SP. c-Abl tyrosine kinase regulates cardiac growth and development. Proc Natl Acad Sci USA 107: 1136–1141, 2010.
53. Saad SY, Alkharfy KM, Arafah MM. Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. J Pharm Pharmacol 58: 567–573, 2006.
54. Sardão VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol Toxicol 25: 227–243, 2009.
55. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461: 109–113, 2009.
56. Singh KK, Shukla PC, Quan A, Lovren F, Pan Y, Wolfstadt JI, Gupta M, Al-Omran M, Leong-Poi H, Teoh H, Verma S. Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. Biochem Biophys Res Commun 411: 421–426, 2011.
57. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792, 2001.
58. Srinivasan D, Kaetzel DM, Plattner R. Reciprocal regulation of Abl and receptor tyrosine kinases. Cell Signal 21: 1143–1150, 2009.
59. Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 66: 5648–5655, 2006.
60. Stanley BA, Sivakumaran V, Shi S, McDonald I, Lloyd D, Watson WH, Aon MA, Paolocci N. Thioredoxin reductase-2 is essential for keeping low levels of H(2)O(2) emission from isolated heart mitochondria. J Biol Chem 286: 33669–33677, 2011.
61. Stone JR, Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 8: 243–270.
62. Sysa-Shah P, Xu Y, Guo X, Belmonte F, Kang B, Bedja D, Pin S, Tsuchiya N, Gabrielson K. Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice. PLoS One 7: e42805, 2012.
63. Tahara EB, Navarete FD, Kowaltowski AJ. Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species generation. Free Radic Biol Med 46: 1283–1297, 2009.
64. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49: 241–248, 2007.
65. Tan-chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23: 7811–7819, 2006.
66. Tanos B, Pendergast AM. Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem 281: 32714–32723, 2006.
67. Timolati F, Ott D, Pentassuglia L, Giraud MN, Perriard JC, Suter TM, Zuppinger C. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 41: 845–854, 2006.
68. Vuorenpää H, Ikonen L, Kujala K, Huttala O, Sarkanen JR, Ylikomi T, Aalto-Setälä K, Heinonen T. Novel in vitro cardiovascular constructs composed of vascular-like networks and cardiomyocytes. In Vitro Cell Dev Biol Anim 50: 275–286, 2014.
69. Wang GW, Kang YJ. Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels. J Pharmacol Exp Ther 288: 938–944, 1999.
70. Wang GW, Schuschke DA, Kang YJ. Metallothionein-overexpressing neonatal mouse cardiomyocytes are resistant to H2O2 toxicity. Am J Physiol Heart Circ Physiol 276: H167–H175, 1999.
71. Watkins SJ, Borthwick GM, Arthur HM. The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. Vitr Cell Dev Biol Anim 47: 125–131, 2011.
72. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137, 2001.